Hedgehog signaling pathway as a therapeutic target for ovarian cancer

Cancer Epidemiology

Volumn 40, Issue , 2016, Pages 152-157

  Li, Haixia ^a   Li, Jinghua ^a   Feng, Limin ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hedgehog; Ovarian cancer; Targeted therapy

Indexed keywords

CYCLOPAMINE; PACLITAXEL; PATIDEGIB; SONIC HEDGEHOG PROTEIN; SONIDEGIB; VISMODEGIB; ANTINEOPLASTIC AGENT;

ANOIKIS; APOPTOSIS; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL DIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG CANCER; METASTASIS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FEMALE; METABOLISM; OVARIAN NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HEDGEHOG PROTEINS; HUMANS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84960084793     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2015.11.014     Document Type: Review

References (66)

1. Varjosalo M., Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008, 22:2454-2472.
2. Petrova R., Joyner A.L. Roles for hedgehog signaling in adult organ homeostasis and repair. Development 2014, 141:3445-3457.
3. Bhattacharya R., Kwon J., Ali B., Wang E., Patra S., Shridhar V., et al. Role of hedgehog signaling in ovarian cancer. Clin. Cancer Res. 2008, 14:7659-7666.
4. Hui M., Cazet A., Nair R., Watkins D.N., O'Toole S.A., Swarbrick A. The hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res. 2013, 15:203.
5. Lee S.J., Do I.G., Lee J., Kim K.M., Jang J., Sohn I., et al. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013, 8:271-280.
6. Kim Y., Kim M.O., Shin J.S., Park S.H., Kim S.B., Kim J., et al. Hedgehog signaling between cancer cells and hepatic stellate cells in promoting cholangiocarcinoma. Ann. Surg. Oncol. 2014, 21:2684-2698.
7. Lauth M., Toftgard R. Hedgehog signaling and pancreatic tumor development. Adv. Cancer Res. 2011, 110:1-17.
8. Kugler M.C., Joyner A.L., Loomis C.A., Munger J.S. Sonic hedgehog signaling in the lung. From development to disease. Am. J. Respir. Cell Mol. Biol. 2015, 52:1-13.
9. Irvine D.A., Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012, 119:2196-2204.
10. Gonnissen A., Isebaert S., Haustermans K. Targeting the hedgehog signaling pathway in cancer: beyond smoothened. Oncotarget 2015, 6:13899-13913.
11. Mazumdar T., DeVecchio J., Agyeman A., Shi T., Houghton J.A. The GLI genes as the molecular switch in disrupting hedgehog signaling in colon cancer. Oncotarget 2011, 2:638-645.
12. Stone D.M., Hynes M., Armanini M., Swanson T.A., Gu Q., Johnson R.L., et al. The tumour-suppressor gene patched encodes a candidate receptor for sonic hedgehog. Nature 1996, 384:129-134.
13. Taipale J., Cooper M.K., Maiti T., Beachy P.A. Patched acts catalytically to suppress the activity of smoothened. Nature 2002, 418:892-897.
14. Lum L., Beachy P.A. The hedgehog response network: sensors, switches, and routers. Science 2004, 304:1755-1759.
15. Wilson C.W., Chuang P.T. Mechanism and evolution of cytosolic hedgehog signal transduction. Development 2010, 137:2079-2094.
16. Teglund S., Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim. Biophys. Acta 2010, 2:181-208.
17. Yue S., Chen Y., Cheng S.Y. Hedgehog signaling promotes the degradation of tumor suppressor sufu through the ubiquitin-proteasome pathway. Oncogene 2009, 28:492-499.
18. Javelaud D., Pierrat M.J., Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS Lett. 2012, 586:2016-2025.
19. Brechbiel J., Miller-Moslin K., Adjei A.A. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat. Rev. 2014, 40:750-759.
20. Mangelberger D., Kern D., Loipetzberger A., Eberl M., Aberger F. Cooperative hedgehog-EGFR signaling. Front. Biosci. 2012, 17:90-99.
21. Hahn H., Wicking C., Zaphiropoulous P.G., Gailani M.R., Shanley S., Chidambaram A., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-851.
22. Jones D.T., Jager N., Kool M., Zichner T., Hutter B., Sultan M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488:100-105.
23. Parsons D.W., Li M., Zhang X., Jones S., Leary R.J., Lin J.C., et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011, 331:435-439.
24. Pugh T.J., Weeraratne S.D., Archer T.C., Pomeranz Krummel D.A., Auclair D., Bochicchio J., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012, 488:106-110.
25. Dierks C., Grbic J., Zirlik K., Beigi R., Englund N.P., Guo G.R., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 2007, 13:944-951.
26. Chen X., Horiuchi A., Kikuchi N., Osada R., Yoshida J., Shiozawa T., et al. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: it's inhibition leads to growth suppression and apoptosis. Cancer Sci. 2007, 98:68-76.
27. Liao X., Siu M.K., Au C.W., Wong E.S., Chan H.Y., Ip P.P., et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009, 30:131-140.
28. Yang L., He J., Huang S., Zhang X., Bian Y., He N., et al. Activation of hedgehog signaling is not a frequent event in ovarian cancers. Mol. Cancer 2009, 8:1476-4598.
29. Ciucci A., De Stefano I., Vellone V.G., Lisi L., Bottoni C., Scambia G., et al. Expression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival. PLoS One 2013, 8:e60145.
30. Takebe N., Miele L., Harris P.J., Jeong W., Bando H., Kahn M., et al. Targeting notch, hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat. Rev. Clin. Oncol. 2015, 12:445-464.
31. Campbell V., Copland M. Hedgehog signaling in cancer stem cells: a focus on hematological cancers. Stem Cells Cloning 2015, 8:27-38.
32. Ferent J., Cochard L., Faure H., Taddei M., Hahn H., Ruat M., et al. Genetic activation of hedgehog signaling unbalances the rate of neural stem cell renewal by increasing symmetric divisions. Stem Cell Rep. 2014, 3:312-323.
33. Ray A., Meng E., Reed E., Shevde L.A., Rocconi R.P. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int. J. Oncol. 2011, 39:797-804.
34. Kong Y., Peng Y., Liu Y., Xin H., Zhan X., Tan W. Twist1 and snail link hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters. Stem Cells 2015, 33:1063-1074.
35. Singh S., Chitkara D., Mehrazin R., Behrman S., Wake R., Mahato R. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS One 2012, 7:e40021.
36. Tripathi K., Mani C., Barnett R., Nalluri S., Bachaboina L., Rocconi R., et al. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J. Biol. Chem. 2014, 289:31513-31525.
37. Zahreddine H.A., Culjkovic-Kraljacic B., Assouline S., Gendron P., Romeo A.A., Morris S.J., et al. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature 2014, 511:90-93.
38. Steg A.D., Bevis K.S., Katre A.A., Ziebarth A., Dobbin Z.C., Alvarez R.D., et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res. 2012, 18:869-881.
39. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
40. Huang R.Y., Chung V.Y., Thiery J.P. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr. Drug Targets 2012, 13:1649-1653.
41. Vergara D., Merlot B., Lucot J.P., Collinet P., Vinatier D., Fournier I., et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010, 291:59-66.
42. Islam S.S., Mokhtari R.B., Noman A.S., Uddin M., Rahman M.Z., Azadi M.A., et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol. Carcinog. 2015, 1. (Epub ahead of print).
43. Liu Q., Sheng W., Dong M., Dong X., Dong Q., Li F. Gli1 promotes transforming growth factor-beta1- and epidermal growth factor-induced epithelial to mesenchymal transition in pancreatic cancer cells. Surgery 2015, 158:211-224.
44. Della Corte C.M., Bellevicine C., Vicidomini G., Vitagliano D., Malapelle U., Accardo M., et al. SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer. Clin. Cancer Res. 2015, 29. (Epub ahead of print).
45. Ke Z., Caiping S., Qing Z., Xiaojing W. Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K/AKT pathway. Med. Oncol. 2015, 32:368.
46. Taddei M.L., Giannoni E., Fiaschi T., Chiarugi P. Anoikis an emerging hallmark in health and diseases. J. Pathol. 2012, 226:380-393.
47. Sakamoto S., Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol. Aspects Med. 2010, 31:205-214.
48. Carduner L., Picot C., Leroy-Dudal J., Blay L., Kellouche S., Carreiras F. Cell cycle arrest or survival signaling through αv integrins, activation of PKC and ERK1/2 lead to anoikis resistance of ovarian cancer spheroids. Exp. Cell Res. 2014, 320:329-342.
49. Lui V.W., Yau D.M., Wong E.Y., Ng Y.K., Lau C.P., Ho Y., Cucurbitacin I., et al. Elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 2009, 30:2085-2094.
50. Kandala P.K., Srivastava S.K. Diindolylmethane-mediated Gli1 protein suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J. Biol. Chem. 2012, 287:28745-28754.
51. Yun J.I., Kim H.R., Park H., Kim S.K., Lee J. Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer. Arch. Pharm. Res. 2012, 35:1317-1333.
52. Lee S.T., Welch K.D., Panter K.E., Gardner D.R., Garrossian M., Chang C.W. Cyclopamine from cyclops lambs to cancer treatment. J. Agric. Food Chem. 2014, 62:7355-7362.
53. Huang Yu-Chuen, Clifford Chao K.S., Liao Hui-Fen, Chen Yu-Jen Targeting sonic hedgehog signaling by compounds and derivatives from natural products. Evid. Based Complement. Altern. Med. 2013, 2013:5. Article ID 748587. 10.1155/2013/748587.
54. Eimer S., Dugay F., Airiau K., Avril T., Quillien V., Belaud-Rotureau M.A., et al. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro. Oncol. 2012, 14:1441-1451.
55. Steg A.D., Katre A.A., Bevis K.S., Ziebarth A., Dobbin Z.C., Shah M.M., et al. Smoothened antagonists reverse taxane resistance in ovarian cancer. Mol. Cancer Ther. 2012, 11:1587-1597.
56. Lauth M., Bergstrom A., Shimokawa T., Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8455-8460.
57. Srivastava R.K., Kaylani S.Z., Edrees N., Li C., Talwelkar S.S., Xu J., et al. GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. Oncotarget 2014, 5:12151-12165.
58. Huang L., Walter V., Hayes D.N., Onaitis M. Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. Clin. Cancer Res. 2014, 20:1566-1575.
59. Agyeman A., Mazumdar T., Houghton J.A. Regulation of DNA damage following termination of hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget 2012, 3:854-868.
60. Chen Q., Xu R., Zeng C., Lu Q., Huang D., Shi C., et al. Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin beta4-mediated FAK signaling. PLoS One 2014, 9:e88386.
61. Erdem G., Sendur M., Ozdemir N., Yazici O., Zengin N. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr. Med. Res. Opin. 2015, 31:743-756.
62. Kaye S., Fehrenbacher L., Holloway R., Amit A., Karlan B., Slomovitz B., et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin. Cancer Res. 2012, 18:6509-6518.
63. ClinicalTrials.gov. Available from: http://www.clinicaltrials.gov.
64. Jimeno A., Weiss G.J., Miller W.H., Gettinger S., Eigl B.J., Chang A.L., et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 2013, 19:2766-2774.
65. Burness C.B. Sonidegib: first global approval. Drugs 2015, 75:1559-1566.
66. Steg A.D., Burke M.R., Amm H.M., Katre A.A., Dobbin Z.C., Jeong D.H., et al. Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer. Oncotarget 2014, 5:7065-7080.